ESSA Pharma Inc.

Case Overview
32 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/25/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: ESSA Pharma Inc. |
Court: | Court: Eastern District of Wisconsin |
Case Number: | Case Number: 1:25cv00124 |
Class Period: | Class Period: 12/12/2023 - 10/31/2024 |
Ticker: | Ticker: EPIX |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Wisconsin on behalf of those who acquired ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQ:EPIX) securities during the period from December 12, 2023, through October 31, 2024 (“the Class Period”). Investors have until March 25, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On October 21, 2024, during after-market hours, ESSA issued a press release announcing its decision to terminate Phase 2 of its M-E Combination Study, citing a “protocol-specified interim review of the safety, PK [pharmacokinetics] and efficacy data, which showed a much higher rate of PSA90 response in patients treated with enzalutamide monotherapy…than were expected based upon historical data” and “no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.” The Company further advised that “a futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study” and that, “as part of the effort to focus its resources,” it was “planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination with other agents.” On this news, the price of ESSA shares declined by $3.80 per share, or approximately 73.08%, from $5.20 per share on October 31, 2024, to close at $1.40 on November 1, 2024.
The complaint alleges that Defendants, throughout the Class Period, made false and/or misleading statements and/or failed to disclose that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe; and (3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint.
On October 21, 2024, during after-market hours, ESSA issued a press release announcing its decision to terminate Phase 2 of its M-E Combination Study, citing a “protocol-specified interim review of the safety, PK [pharmacokinetics] and efficacy data, which showed a much higher rate of PSA90 response in patients treated with enzalutamide monotherapy…than were expected based upon historical data” and “no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.” The Company further advised that “a futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study” and that, “as part of the effort to focus its resources,” it was “planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination with other agents.” On this news, the price of ESSA shares declined by $3.80 per share, or approximately 73.08%, from $5.20 per share on October 31, 2024, to close at $1.40 on November 1, 2024.
The complaint alleges that Defendants, throughout the Class Period, made false and/or misleading statements and/or failed to disclose that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe; and (3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint.